“Most of the time, there’s no bad news,” says Karen Rizzo, MD, 2015 president of the Pennsylvania Medical Society and a practicing physician in Lancaster. …
This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than does lapatinib (Tykerb), says Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. …
This study, being presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, reveals that when used as a single HER2-targeted therapy in addition to standard chemotherapy, trastuzumab offers a better outcome than does lapatinib (Tykerb), says Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. Dr. Perez is co-chair of ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study). …
Dr Martin Chasen, lead author and medical director, Palliative Care, Ottawa Hospital Cancer Centre, Canada, said: “This agent makes a significant difference in the way people tolerate their chemotherapy. Patients experienced no loss in quality of life and, in fact, many saw meaningful improvements. One of the patients in the rolapitant cohort reported that he had just finished 18 holes of golf one week after receiving chemotherapy…
“Prior to this study, there were a handful of reports describing marked responses to crizotinib in individual patients with ROS1-positive lung tumors,” says Alice Shaw, MD, PhD, of the Massachusetts General Hospital (MGH) Cancer Center, lead author of the NEJM report. “This is the first definitive study to establish crizotinib’s activity in a large group of patients with ROS1-positive lung cancer and to confirm that ROS1 is a bona fide therapeutic target in those patients.” Crizotinib currently is FDA-approved to treat non-small-cell lung cancers (NSCLC) driven by rearrangments in the ALK gene, which make up around 4 percent of cases…
CLEOPATRA was a pivotal phase III study where researchers evaluated the safety and efficacy of pertuzumab, trastuzumb and chemotherapy in 808 patients with previously untreated HER2-positive metastatic breast cancer. …
In Europe, about 70% of patients with cervical cancer are cured by either surgery or chemo-radiotherapy. Those patients with recurrent or secondary cancer have a very poor outlook. Only about 20-30% have tumour shrinkage after conventional chemotherapy and survival is usually less than one year. In the phase II CIRCCa trial, researchers compared two groups of patients with relapsed or metastatic cervical cancer given conventional chemotherapy with carboplatin and paclitaxel plus either cediranib (34 patients) or an identical looking placebo tablet (35 patients). …
“Oncology is an exceptionally rewarding career, but it can be demanding and stressful at times,” said Dr Susana Banerjee, lead author of the study and a consultant medical oncologist at The Royal Marsden NHS Trust in London, UK. “Oncologists make complex decisions about cancer management, supervise the use of toxic therapies, work long hours, and continually face patients suffering and dying,” she said…
The research is described in a paper published online September 18, 2014, in Immunity, a Cell Press journal. Myeloid-derived suppressor cells (MDSCs) are involved in cancer, inflammation and infection. …
The study, using a national database of more than 100,000 women treated during the last decade, found that today nationally radiation oncologists are less likely to use radiotherapy in women older than 70 with early-stage estrogen-receptor-positive breast cancer and that when they do, treatment is appropriately less-intensive. This follows a randomized trial demonstrating low rates of recurrence in women who don’t receive radiotherapy after lumpectomy, provided they take endocrine therapy. This confirms radiation oncologists are responding to a growing impetus to keep medical practices current and cost-effective, said first author Charles Rutter, M.D., a radiation oncology resident in Yale’s School of Medicine. …